Bayer and Boehringer present data on competing oral HER2 drugs at WCLC, as they run phase 3 trials in NSCLC with HER2 activations. Skip to main content Wednesday 25 June 2025 . BlueSky ...

Results of Ideate-Lung01 trial at WCLC back up MSD and Daiichi Sankyo's decision to move anti-B7-H3 ADC I-Dxd into phase 3 for small cell lung cancer.